阿托莫西汀
哌醋甲酯
兴奋剂
医学
注意缺陷多动障碍
荟萃分析
托莫西汀
血压
不利影响
临床试验
出版偏见
内科学
儿科
精神科
作者
Leonie Hennissen,Mireille J. Bakker,Tobias Banaschewski,Sara Carucci,David Coghill,Marina Danckaerts,Regina Dittmann,Chris Hollis,Hanna Kovshoff,Suzanne McCarthy,Péter Nagy,Edmund Sonuga‐Barke,Ian Chi Kei Wong,Alessandro Zuddas,Éric Rosenthal,Jan K. Buitelaar
出处
期刊:CNS Drugs
[Adis, Springer Healthcare]
日期:2017-02-23
卷期号:31 (3): 199-215
被引量:212
标识
DOI:10.1007/s40263-017-0410-7
摘要
Statistically significant pre-post increases of SBP, DBP and HR were associated with AMP and ATX treatment in children and adolescents with ADHD, while MPH treatment had a statistically significant effect only on SBP in these patients. These increases may be clinically significant for a significant minority of individuals that experience larger increases. Since increased BP and HR in general are considered risk factors for cardiovascular morbidity and mortality during adult life, paediatric patients using ADHD medication should be monitored closely and regularly for HR and BP.
科研通智能强力驱动
Strongly Powered by AbleSci AI